Phase 2 N=405 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic Syndrome
Primary: Blood Glucose Level — 6.05; 6.43; 4.58; 14.5 mmole/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
Phase 2 N=40 Implications for Treatment of the Metabolic Syndrome
Metabolic Syndrome
Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
Phase 2 N=24 Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Metabolic Syndrome X
Primary: Triglycerides Levels at Week 12 — 210.6; 235.8 mg/dL — p=0.131
N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
Phase 2 N=28 Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Metabolic Syndrome
Primary: Waist Circumference (WC) — 98.9; 102.1 cm
Phase 4 N=70 Mechanisms Underlying Metabolic Syndrome in Obesity
Metabolic Syndrome · Insulin Resistance · Prediabetes
Primary: Change in Insulin Sensitivity Using FSIGT — 1.7; 2.4; 7.02 FSIGT units (x10^-4/min/uU/ml)
N/A N=60 Korean Red Ginseng and Metabolic Syndrome
Metabolic Syndrome
Primary: Change in the Pre- and Post-treatment Systolic Blood Pressure — 129.5; 134.5; 122.6; 127.5 mm Hg
N/A N=24 Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
Metabolic Syndrome X
Primary: Fasting Glucose Levels at Week 12 — 5.7; 5.9 mmol/L — p=0.240
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
Phase 4 N=36 Oral Contraceptives in the Metabolic Syndrome
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L
Phase 2 N=12 Blood Lipopolysaccharide (LPS) Rifaximin Study
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
Phase 2 N=24 Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
Metabolic Syndrome X
Primary: Triglyceride Levels at Week 12 — 148.0; 199.9 mg/dL — p=0.021
Phase 4 N=24 Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
Hypertension
Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…
Phase 3 N=24 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
Metabolic Syndrome X
Primary: Waist Circumference at Week 12. — 97.6; 97.2 centimeters — p=<0.001
Early Phase 1 N=46 Assessment of Renal Function by Multiparametric MRI
Renal Impairment
Primary: T1 Time — 1500 ms
Phase 2 N=12 Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Metabolic Syndrome
Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis
Phase 3 N=1,143 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Phase 2 N=35 Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic Syndrome X · Overweight · Hypertension
Primary: Insulin Sensitivity — .56; 0.55; 0.66; 0.70 % suppression inf rate 56 pmol/m2/min
N/A N=36 Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome
Metabolic Syndrome
Primary: Body Weight — 75.2; 74.97; 74.41; 74.39 kg
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio
Phase 2 N=39 Melatonin and the Metabolic Syndrome
Metabolic Syndrome
Primary: Metabolic Syndrome Components — -2.7; 4.7 mmHg — p=0.013
N/A N=50 Exercise, Statins, and the Metabolic Syndrome
Metabolic Syndrome · Obese · Sedentary
Primary: % Change in VO2max (Fitness) — 0; 10; 1.5 percentage change of VO2max — p=<0.05
N/A N=67 Metabolic Syndrome in PCOS: Precursors and Interventions
Polycystic Ovary Syndrome · Metabolic Syndrome
Primary: Change in Low-density Lipoprotein (LDL) Levels Over the Study Period — -6; -9; -7 mg/dL
Phase 4 N=607 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
Metabolic Syndrome
Primary: Change in Total Cholesterol (TC), High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides (TG) Levels From Baseline…
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Phase 4 N=97 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Metabolic Syndrome
Primary: Basal HDL-cholesterol Level — 39.5 mg/dL
Phase 3 N=40 The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Metabolic Syndrome
Primary: Flow Mediated Vasodilation — 9.5; 10.8; 10.5; 10.9 percentage of vasodilation
N/A N=40 Study of TNF-Antagonism in the Metabolic Syndrome (II)
Metabolic Syndrome
Primary: C-reactive Protein (CRP) — 0.61; 0.68 Log10 mg/L — p=0.20